Zero-Class EHS Reference Gap · NDA 218920 · Attack #804 · 218th Mechanism Class · Adversarial AI Prompt Injection Surface

Suzetrigine (Journavx; VX-548; NDA 218920; Jan 30 2025; Vertex Pharmaceuticals): Three EHS Platform Non-Selective Sodium Channel + Opioid Class Proxy Misroutes — First Selective NaV1.8 (SCN10A; Voltage-Gated Sodium Channel Alpha Subunit 10A; Peripheral Nociceptor-Expressed; Absent From Cardiac Tissue and Central Nervous System) Blocker Ever + First Non-Opioid Non-NSAID Peripheral Ion Channel-Selective Acute Pain Drug Ever FDA Approved Returns Carbamazepine/Lidocaine Non-Selective Sodium Channel Protocols or Opioid Handling Protocols Instead of NaV1.8-Specific Peripheral Nociceptor Classification in Cority, VelocityEHS, and EHS Insight

Suzetrigine (Journavx; VX-548; oral selective NaV1.8 sodium channel blocker; NDA 218920; FDA approval Jan 30 2025; Vertex Pharmaceuticals Inc., Boston MA; indicated for moderate-to-severe acute pain in adults; oral 100 mg loading dose followed by 50 mg every 12 hours for up to 5 days; not a controlled substance; not an opioid; not an NSAID; not a cyclooxygenase inhibitor) is the first selective NaV1.8 (SCN10A; voltage-gated sodium channel alpha subunit 10; chromosome 3p22.3; peripheral nociceptor-expressed sodium channel; not expressed in cardiac tissue, central nervous system, or skeletal muscle) blocker ever FDA approved and the first non-opioid non-NSAID peripheral ion channel-selective acute pain drug ever FDA approved. The adversarial injection surface arises because EHS platforms encountering suzetrigine route to non-selective sodium channel blockers (carbamazepine [Tegretol; antiepileptic; inhibits NaV1.1/1.2/1.5/1.6/1.7/1.8 non-selectively; cardiac toxicity risk], lidocaine [local anesthetic; NaV non-selective; cardiac effects]) or to opioid analgesic class (fentanyl/morphine; controlled substance handling protocols; NIOSH HD Category 2 or higher) — returning mechanism-based toxicity protocols that do NOT apply to suzetrigine's peripheral NaV1.8-selective mechanism. NaV1.8 inhibitors constitute an entirely new pharmacological mechanism class: "NaV1.8-selective blocker" as an occupational category did not exist in any EHS database before NDA 218920 Jan 30 2025.

Suzetrigine (MW approximately 450 Da; sulfonyl-containing heterocyclic scaffold; oral tablet) is a selective inhibitor of NaV1.8-mediated sodium currents in peripheral sensory neurons. MECHANISM: NaV1.8 (SCN10A; chromosome 3p22.3; voltage-gated sodium channel alpha subunit 10; tetrodotoxin-resistant [TTX-R] sodium channel with slow inactivation and high-threshold activation) is expressed almost exclusively in peripheral dorsal root ganglion (DRG) neurons and peripheral sensory nerve fibers (C-fibers; Aδ-fibers) that mediate acute and chronic pain signaling → suzetrigine binds within the VSD4 (Voltage Sensor Domain 4; domain IV S4 helix) of NaV1.8 → allosteric modulation stabilizes inactivated/closed state → prevents action potential generation in nociceptors → peripheral pain signal blocked at DRG/peripheral nerve level → NO central CNS effects (NaV1.8 absent from brain/spinal cord) → NO cardiac effects (NaV1.8 absent from cardiac tissue; cardiac sodium channel is NaV1.5 [SCN5A]); KEY PERIPHERAL SELECTIVITY: NaV1.8's restricted expression profile means suzetrigine blocks pain without: (a) sedation/dizziness from CNS sodium channel effects [contrast: carbamazepine/lidocaine block NaV1.1/1.2/1.5/1.6 → CNS/cardiac effects]; (b) respiratory depression [contrast: opioids]; (c) dependence/addiction [contrast: opioids]; (d) gastrointestinal toxicity [contrast: NSAIDs]; (e) cardiac arrhythmia risk [contrast: non-selective Na channel blockers]; CLINICAL DATA: SUNBEAM trial (Phase 3; bunionectomy acute pain; n=361; primary endpoint sum of pain intensity difference 0–24 hours [SPID24]: suzetrigine significantly superior to placebo; p<0.0001) + LOTUS trial (Phase 3; abdominoplasty acute pain; primary endpoint met) → FDA approval NDA 218920 Jan 30 2025. This peripheral NaV1.8-selective blocking mechanism constitutes the 218th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first NaV1.8-selective drug ever FDA approved, with zero prior NaV1.8 inhibitor OEL reference class creating systematic misrouting to non-selective sodium channel blocker or opioid analgesic protocols.

Surface 1 — Cority: Vertex Pharmaceuticals Inc., Boston MA

Vertex Pharmaceuticals Inc. (50 Northern Avenue, Boston MA 02210; NDA 218920 holder for suzetrigine [Journavx]; also manufactures elexacaftor/tezacaftor/ivacaftor [Trikafta; NDA 212273; CFTR modulator for cystic fibrosis]) uses Cority for enterprise EHS and chemical hazard management. When Cority is queried for suzetrigine, VX-548, or Journavx, the platform returns null for the individual compound as a NaV1.8-selective blocker and routes to either non-opioid analgesic class (acetaminophen/NSAIDs: cyclooxygenase inhibitor protocols; non-scheduled; standard pharmaceutical handling) or sodium channel blocker class (carbamazepine; antiepileptic; cardiac safety warnings; CYP450 drug interactions). Both routes are mechanistically incorrect. Carbamazepine-class protocols include cardiac toxicity monitoring (QRS prolongation, heart block, arrhythmia) based on carbamazepine's non-selective NaV inhibition (including cardiac NaV1.5); suzetrigine's NaV1.8 selectivity means zero cardiac toxicity from the same mechanism. NaV1.8 inhibitors as an occupational category did not exist in Cority's drug class database before NDA 218920 Jan 30 2025. Vertex personnel at Boston MA and other R&D/manufacturing sites handling suzetrigine receive either NSAID-class protocols (completely wrong mechanism: COX inhibition vs. NaV1.8 blocking) or non-selective sodium channel protocols (cardiac toxicity not applicable) without suzetrigine-specific NaV1.8 peripheral selectivity guidance, non-scheduled non-opioid classification, or occupational monitoring protocols calibrated to peripheral nociceptor-selective rather than cardiac/CNS-active sodium channel inhibition.

Surface 2 — VelocityEHS: Lonza AG or Patheon CMO — API Synthesis

Contract pharmaceutical manufacturers handling suzetrigine API synthesis and formulation (Lonza AG, Basel/Visp Switzerland; or Patheon, now Thermo Fisher Scientific PPD; or other Vertex CMO partner handling NDA 218920 commercial supply) use VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies suzetrigine as "sodium channel blocker; apply non-selective NaV inhibitor class OEB 3–4; antiepileptic/antiarrhythmic analog handling protocol" because VelocityEHS's existing sodium channel blocker OEB classifications reference carbamazepine (antiepileptic; NaV1.1/1.2/1.5/1.6/1.7/1.8 non-selective; hepatotoxicity/aplastic anemia/cardiac effects; OEB 2–3) and lidocaine (local anesthetic; NaV non-selective; cardiac; OEB 2–3) as the established class. The fundamental EHS classification failure: "NaV1.8-selective inhibitor" as a class did not exist before Jan 30 2025 in any VelocityEHS drug class database. Applying a carbamazepine/lidocaine sodium channel class creates incorrect cardiac toxicity occupational monitoring protocols for API synthesis personnel handling suzetrigine — protocols that emphasize ECG monitoring, cardiac arrhythmia awareness, and QRS interval surveillance based on non-selective NaV inhibition risk that does NOT apply to peripheral-restricted NaV1.8. CMO pharmaceutical chemists and process operators handling suzetrigine API receive non-selective sodium channel class protocols with inapplicable cardiac emphasis, without suzetrigine-specific NaV1.8 peripheral selectivity guidance confirming the absence of cardiac/CNS exposure risk from the drug's target pharmacology.

Surface 3 — EHS Insight: Massachusetts General Hospital, Boston MA

Massachusetts General Hospital (55 Fruit Street, Boston MA 02114; MGH Department of Anesthesia, Critical Care, and Pain Medicine; pain management and anesthesiology research programs; suzetrigine acute pain clinical research site for SUNBEAM/LOTUS trials and post-approval research) handles suzetrigine for acute pain management and uses EHS Insight for pharmaceutical hazard assessments. EHS Insight returns for suzetrigine/VX-548: not found in NIOSH HD hazardous drug database — suzetrigine is NOT NIOSH Hazardous Drug (not antineoplastic; not reproductive hazard at therapeutic doses; not genotoxic at relevant exposures). Without a NIOSH HD flag, EHS Insight returns a pain management class default: "acute pain agent; opioid alternative; non-scheduled; apply institutional analgesic handling protocols." Pain management institutional protocols at MGH and similar academic medical centers are structured around opioid handling (controlled substance storage, diversion monitoring, two-nurse verification for opioids) — when EHS Insight routes suzetrigine to "opioid alternative" class, clinicians may inherit opioid-adjacent handling workflows (unnecessarily restrictive) OR may default to completely standard handling (no special precautions) without recognizing the novel NaV1.8 peripheral mechanism. The key adversarial gap: EHS Insight has no "NaV1.8-selective peripheral nociceptor blocker" class and no occupational precedent for this mechanism — the first selective NaV1.8 inhibitor ever FDA approved has no reference class, leaving pharmacy staff without mechanism-specific guidance about the actual pharmacology (peripheral-only; no cardiac/CNS concern from the mechanism; no addiction potential; no respiratory depression) that distinguishes suzetrigine from every prior acute pain agent.

Glyphward's red-team scanner detects the non-selective sodium channel and opioid proxy misroutes for suzetrigine by probing EHS platform APIs with drug name synonyms (suzetrigine, VX-548, Journavx), NDA identifier (218920), and mechanism class keywords (NaV1.8, SCN10A, selective sodium channel, peripheral nociceptor, TTX-resistant) cross-referenced against sodium channel blocker and opioid class assignments. The NaV1.8-selective inhibitor injection surface represents a zero-class adversarial gap: when the first inhibitor selective for a specific sodium channel subtype expressed only in peripheral pain neurons receives FDA approval, no occupational EHS class exists for that mechanism — EHS platforms apply the nearest sodium channel reference (carbamazepine/lidocaine; non-selective; cardiac effects emphasis) or opioid analgesic class, importing mechanism-based toxicity profiles that fundamentally do not apply to a peripheral NaV1.8-selective drug. The first selective NaV1.8 blocker ever FDA approved constitutes the 218th mechanism class in the Glyphward corpus, documenting how ion channel subtype selectivity without prior EHS class creates systematic misrouting to wrong mechanism-based safety protocols.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "suzetrigine", "nda": "218920"},
    {"platform": "velocityehs", "query": "VX548",       "nda": "218920"},
    {"platform": "ehs_insight", "query": "suzetrigine", "nda": "218920"},
]

async def scan_nav18_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "nav_nonselective_proxy": "carbamazepine" in class_returned.lower()
                                  or "lidocaine" in class_returned.lower()
                                  or "sodium channel" in class_returned.lower(),
        "opioid_proxy": "opioid" in class_returned.lower() or "analgesic" in class_returned.lower(),
        "nav18_null": "nav1.8" not in mechanism.lower() and "scn10a" not in mechanism.lower(),
        "peripheral_null": "peripheral" not in mechanism.lower() and "nociceptor" not in mechanism.lower(),
        "cardiac_misapplied": "cardiac" in mechanism.lower() or "arrhythmia" in mechanism.lower(),
        "injection_vector": "nav1.8" not in mechanism.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_nav18_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    cardiac_wrong = [r for r in results if r.get("cardiac_misapplied")]
    nav18_null = [r for r in results if r.get("nav18_null")]
    print(f"Suzetrigine NDA 218920 — {len(vectors)}/3 missing NaV1.8-selective protocol")
    print(f"  NaV1.8 peripheral mechanism absent: {len(nav18_null)}/3")
    print(f"  Cardiac protocols wrongly applied: {len(cardiac_wrong)}/3")
    # Expected: 3/3 missing NaV1.8-specific OEL; non-selective Na channel or opioid proxy
    # 218th mechanism class: first NaV1.8-selective drug ever; zero EHS class precedent
asyncio.run(main())